Shenzhen Neptunus Interlong Bio-technique Company Limited
HKSE: 8329.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Feng Zhang
- Employees
- 1,485
- Headquarters
- Shenzhen, China
- IPO year
- 2005
- Market cap
- HK$208.1M
- Website
- https://www.interlong.com
Loading 8329…
Loading profile data…Frequently asked questions about 8329
What does Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) do?
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products. In...
Where does 8329.HK trade?
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) trades on the Hong Kong Stock Exchange.
What sector is 8329.HK in?
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Shenzhen Neptunus Interlong Bio-technique Company Limited?
Feng Zhang is the chief executive officer of Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK).
Where is Shenzhen Neptunus Interlong Bio-technique Company Limited headquartered?
Shenzhen Neptunus Interlong Bio-technique Company Limited is headquartered in China.
Does 8329.HK pay a dividend?
Yes — Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) paid a trailing twelve-month dividend of HKD 0.01 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 8329.HK go public?
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) completed its initial public offering in 2005.